Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I5T-MC-AACI
2023-507303-55-00Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Donanemab with Placebo (2 arms). Primary endpoint: Change from baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (overall population). Started Oct 2024; status: completed.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2023-507303-55-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507303-55-00.